{
  "meta": {
    "timestamp": "2025-01-06T12:47:26.063730",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Myriad Genetics, Inc.",
      "symbol": "MYGN",
      "analysis": {
        "historical": {
          "risk_score": 60,
          "key_risks": [
            "Reimbursement challenges from insurers and government payers",
            "Intense competition in the genetic testing market",
            "Legal and regulatory issues, including patent disputes",
            "Data privacy concerns and compliance with stringent regulations",
            "Operational challenges and potential quality control issues"
          ],
          "controversies": [
            "Supreme Court ruling in 2013 against patenting naturally occurring gene sequences",
            "Mixed investor sentiment with some reducing holdings"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Data privacy concerns related to sensitive genetic information"
          ],
          "governance_issues": [
            "Potential operational inefficiencies highlighted in the Quality, Innovation, and Corporate Responsibility Report"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Revisiting the Myriad gene patenting case a decade after decision",
              "snippet": "Myriad Genetics, Inc. At the time, ... In 1994 and 1995, biotechnology company Myriad Genetics won this race and filed patent applications covering the locations and sequences of the BRCA1 and BRCA2 breast cancer genes, eventually resulting in 7 different patents. These patents gave Myriad Genetics exclusive rights to cancer screening and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590686+00:00",
              "published_date": null,
              "source_hash": "d4fe86c828920b3d9672e769f703de3f"
            },
            {
              "url": "",
              "title": "Supreme Court to Myriad Genetics: Synthetic DNA is Patentable but ...",
              "snippet": "Myriad Genetics, Inc., the Supreme Court ruled that synthetically created DNA is patentable, but the isolation of unaltered gene sequences is not. ... physicians, patient advocacy groups, and individual patients, a lawsuit was filed against Myriad in 2010, challenging its patents on BRCA1 and BRCA2 and other patents stemming from these two ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590774+00:00",
              "published_date": null,
              "source_hash": "57a482cfcef325089fa2da03de22fe91"
            },
            {
              "url": "",
              "title": "ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.",
              "snippet": "See ibid. (claim 7 of the '282 patent); id., at 930 (claim 1 of the '473 patent); id., at 1028 (claims 1, 6, and 7 of the '492 patent). C Myriad's patents would, if valid, give it the exclusive right to isolate an individual's BRCA1 and BRCA2 genes (or any strand of 15 or more nucleotides within the genes) by breaking the covalent ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590791+00:00",
              "published_date": null,
              "source_hash": "0b58cabc30f664e6666f2ffd4d610d04"
            },
            {
              "url": "",
              "title": "Myriad Genetics Inc. - The New York Times",
              "snippet": "Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590805+00:00",
              "published_date": null,
              "source_hash": "6638f50b523d995cf851a7cd01437a5a"
            },
            {
              "url": "",
              "title": "Myriad board, execs face Del suit over 'misleading' genetic test ...",
              "snippet": "Myriad Genetics Inc investor has sued some of the molecular diagnostic test maker's board members, executives and former CEO in a Delaware state court for allegedly making misleading and false ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590817+00:00",
              "published_date": null,
              "source_hash": "6e03039cda174836e962097cb0e549b8"
            },
            {
              "url": "",
              "title": "The Myriad Gene Patent Case: Trickier Than You Might Think",
              "snippet": "The plaintiffs in this case are a wide range of people, ranging from the Penn lab and others who wanted to offer BRCA testing, through people who claimed that they had been denied the opportunity to have such a test done through Myriad's exercise of its patents. The lawsuit went through a challenge in district court about whether the plaintiffs ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590830+00:00",
              "published_date": null,
              "source_hash": "f8a5f04cfbe97c98c5db41493439f75d"
            },
            {
              "url": "",
              "title": "Myriad: Debate Over Gene Patents Continues - PMC - National Center for ...",
              "snippet": "One of the most hotly debated topics in intellectual property rights is the patentability of genes. Since the Supreme Court's 1980 decision in Diamond v.Chakrabarty, 1 patenting DNA sequences has become common; today there are about 50,000 such patents. A 2009 lawsuit by the American Civil Liberties Union (ACLU) against Myriad Genetics threatens to undo the significant history behind the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:46:57.590843+00:00",
              "published_date": null,
              "source_hash": "a256dfc926d6e3abd1c0c3a29dbd5ca1"
            },
            {
              "url": "",
              "title": "Myriad Genetics - Wikipedia",
              "snippet": "Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States.Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588596+00:00",
              "published_date": null,
              "source_hash": "1d7955d4133571e6a6879a73151d061a"
            },
            {
              "url": "",
              "title": "Myriad Genetics Issues Quality, Innovation, and Corporate ...",
              "snippet": "SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605242+00:00",
              "published_date": null,
              "source_hash": "795ccad39dc5b86aa7e66e0d2596fe3f"
            },
            {
              "url": "",
              "title": "Myriad Genetics Issues Quality, Innovation, and Corporate - GlobeNewswire",
              "snippet": "SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605256+00:00",
              "published_date": null,
              "source_hash": "189b7afafb901703f1b2ad1af9b730ca"
            },
            {
              "url": "",
              "title": "Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report",
              "snippet": "SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:12.288505+00:00",
              "published_date": "2025-01-06T13:26:00+00:00",
              "source_hash": "51f11b047b3045b0c183a4deceb38583"
            },
            {
              "url": "",
              "title": "Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?",
              "snippet": "Myriad Genetics, Inc. MYGN is driving innovation across Oncology, Women's Health and Pharmacogenomics, and heavily invests in labs and digital capabilities. Thecompany's Oncology growth strategy centers on the expansion of companion diagnostics,",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. patent disputes and lawsuits",
              "retrieved_at": "2025-01-06T19:47:01.030048+00:00",
              "published_date": "2024-12-17T12:35:00+00:00",
              "source_hash": "3cd470faef77a73b5ac2467d3671f207"
            },
            {
              "url": "",
              "title": "Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by Fmr LLC",
              "snippet": "Fmr LLC grew its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 23.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:06.453498+00:00",
              "published_date": "2024-12-16T07:24:00+00:00",
              "source_hash": "537403b63fee1c168fdb549c9a8737b4"
            },
            {
              "url": "",
              "title": "Myriad Genetics Releases Quality, Innovation, and Corporate ...",
              "snippet": "Myriad Genetics, Inc. has released its Quality, Innovation, and Corporate Responsibility Report for the period from January 1, 2023, to September 30, 2024, showcasing its dedication to responsible operations in the healthcare sector. ... The necessity of a robust quality management system could imply previous challenges in operational execution ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588528+00:00",
              "published_date": null,
              "source_hash": "18b1e84b18d8afc4cb78faa291c2276d"
            },
            {
              "url": "",
              "title": "Myriad Genetics Issues Quality, Innovation, and Corporate ...",
              "snippet": "Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588541+00:00",
              "published_date": null,
              "source_hash": "08525a217bba25c4a9d5044810fef322"
            },
            {
              "url": "",
              "title": "Myriad Genetics Issues Quality, Innovation, and Corporate ...",
              "snippet": "01/06/2025 - 08:00 AM . SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605267+00:00",
              "published_date": null,
              "source_hash": "4b9634066980467d532568f4b2df7fa2"
            },
            {
              "url": "",
              "title": "Myriad Genetics Reports Third Quarter Financial Results",
              "snippet": "Myriad Genetics' fiscal year 2022 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40.0 million, non-cash amortization associated with acquisitions of approximately $40.0 million and special items such as costs related to transformation initiatives of approximately $15.0 million.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588565+00:00",
              "published_date": null,
              "source_hash": "806f1d84a17d14acb9b8c4dd973c60c2"
            },
            {
              "url": "",
              "title": "Myriad Genetics, Inc. (LON: 0K3W) Company Profile & Overview - Stock ...",
              "snippet": "Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588576+00:00",
              "published_date": null,
              "source_hash": "931de7a73c6ad008f29f213c7b631b26"
            },
            {
              "url": "",
              "title": "Myriad Genetics Reports Third Quarter 2024 Financial Results ... - BioSpace",
              "snippet": "SALT LAKE CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2024 and updated its previously issued financial guidance on business performance for the full-year 2024.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588586+00:00",
              "published_date": null,
              "source_hash": "bb7267e8583aa326d080378e2a5fa48c"
            },
            {
              "url": "",
              "title": "Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates ...",
              "snippet": "Myriad Genetics, Inc. Highlights. Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:03.588606+00:00",
              "published_date": null,
              "source_hash": "fc6e83be26520490222924200e99e7a0"
            },
            {
              "url": "",
              "title": "Myriad Genetics, Inc.",
              "snippet": "Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:06.453422+00:00",
              "published_date": "2018-07-12T01:54:00+00:00",
              "source_hash": "43856ec10b5544d4d8bc3268f87239e8"
            },
            {
              "url": "",
              "title": "Principal Financial Group Inc. Reduces Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)",
              "snippet": "Principal Financial Group Inc. decreased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 4.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:06.453450+00:00",
              "published_date": "2024-12-30T08:09:00+00:00",
              "source_hash": "e9e2970b8bc0fa830fd7abc49f1a5a9a"
            },
            {
              "url": "",
              "title": "Cautious Hold: Myriad Genetics Faces Growth Uncertainty Amid Reimbursement Challenges",
              "snippet": "However, there remains concern over reimbursement issues ... TipRanks Premium journey today. Myriad Genetics (MYGN) Company Description: Myriad Genetics, Inc. engages in the discovery, development ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. reimbursement challenges with insurers",
              "retrieved_at": "2025-01-06T19:47:06.453475+00:00",
              "published_date": "2024-12-10T04:25:00+00:00",
              "source_hash": "b692b36a552e12294511ed3fda30c603"
            },
            {
              "url": "",
              "title": "Privacy Notice - Myriad Genetics",
              "snippet": "Categories of Personal Information Purposes of Use; Personal Information: Name and Contact Information, Demographic Data, Provider Information, Employment-related Information, User Generated Content and Files, Content of Communications, Financial Information, Identifiers and Device Information, Geolocation Data, Internet and Network Activity, Usage Data, Inferences",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.604957+00:00",
              "published_date": null,
              "source_hash": "a0aff79664177ea493f5a983f49367af"
            },
            {
              "url": "",
              "title": "Information Security - Myriad Genetics",
              "snippet": "Myriad Genetics Information Security Myriad Genetics is committed to maintaining the confidentiality, integrity and availability of the data entrusted to us by our patients and customers. As a Covered Entity under HIPAA regulations Myriad has developed a robust information security program which implements the processes and controls necessary ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605062+00:00",
              "published_date": null,
              "source_hash": "a8005f4c16899d2ed09c970dafc4aa4d"
            },
            {
              "url": "",
              "title": "HIPAA Notice of Privacy Practices - Myriad Genetics",
              "snippet": "This Notice describes the privacy practices of Myriad Genetics Laboratories, Inc. (\"MGL\"), Assurex Health, Inc. dba Myriad Neuroscience (\"Assurex\") and Myriad Women's Health, Inc. (\"MWH\") that are covered by the Health Insurance Portability and Accountability Act (\"HIPAA\"). ... For example, we may use de-identified data to ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605186+00:00",
              "published_date": null,
              "source_hash": "0aaa216cb6fcab3b74f01bfc6d0f4b5d"
            },
            {
              "url": "",
              "title": "Myriad Genetics' RiskScore Study Named One of the Top 10 Significant ...",
              "snippet": "SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk \u00ae Hereditary Cancer Test with RiskScore \u00ae study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605279+00:00",
              "published_date": null,
              "source_hash": "cb41196edd23044ae6e4ca86404287c2"
            },
            {
              "url": "",
              "title": "Myriad Genetics, Inc. (LON: 0K3W) Company Profile & Overview - Stock ...",
              "snippet": "Company profile for Myriad Genetics, Inc. (LON: 0K3W) with a description, list of executives, contact details and other key facts. ... a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605294+00:00",
              "published_date": null,
              "source_hash": "87b6627e4d20a80ab03957d1717b1a74"
            },
            {
              "url": "",
              "title": "Myriad Genetics Inc - Company Profile - GlobalData",
              "snippet": "Up-to-date Myriad Genetics Inc company overview including funding information, company profile, key statistics, peer comparison and more. ... genetic expressions and corresponding proteins to assess a person's risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient's likelihood of ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605305+00:00",
              "published_date": null,
              "source_hash": "4d5816f7ded80bf48441e1f8485a37ef"
            },
            {
              "url": "",
              "title": "Myriad Genetics Named to Fast Company's Annual List of World's Most ...",
              "snippet": "Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage SALT LAKE CITY, March 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has been",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:09.605315+00:00",
              "published_date": null,
              "source_hash": "2d7ca8ba5ce5a71e40d784be902b3339"
            },
            {
              "url": "",
              "title": "MYGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Myriad Genetics, Inc. Shareholders Who Lost Money",
              "snippet": "NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. (\"Myriad ... Myriad's genetic test to help ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:12.288570+00:00",
              "published_date": "2024-11-17T22:07:00+00:00",
              "source_hash": "3535778ab4e0065aee8db852d838dd4d"
            },
            {
              "url": "",
              "title": "Myriad Genetics, Inc. (MYGN)",
              "snippet": "The study was selected by SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:12.288600+00:00",
              "published_date": "2024-12-30T22:30:00+00:00",
              "source_hash": "0f49628662669a82165a5ef669acf291"
            },
            {
              "url": "",
              "title": "Leerink Partners Downgrades Myriad Genetics (MYGN)",
              "snippet": "Myriad Genetics Background Information (This description is provided by the company.) Myriad Genetics Inc., is a leading genetic testing ... and small hedge funds. Our data covers the world ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:12.288624+00:00",
              "published_date": "2024-12-10T06:20:00+00:00",
              "source_hash": "d0be32007339d9ecc170b763ddd3ccc1"
            },
            {
              "url": "",
              "title": "UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation",
              "snippet": "Myriad Genetics Background Information (This description is provided by the company.) Myriad Genetics Inc., is a leading genetic testing ... and small hedge funds. Our data covers the world ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Myriad Genetics, Inc. Myriad Genetics, Inc. data privacy and genetic information security",
              "retrieved_at": "2025-01-06T19:47:12.288646+00:00",
              "published_date": "2024-12-11T06:20:00+00:00",
              "source_hash": "614f6c98acece4bca3622d4cf1f2f111"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Myriad Genetics, Inc. patent disputes and lawsuits",
              "rationale": "Investigate ongoing or past legal challenges related to intellectual property and marketing practices",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Myriad Genetics, Inc. reimbursement challenges with insurers",
              "rationale": "Examine the impact of pricing pressures and reimbursement issues on revenue and profitability",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Myriad Genetics, Inc. data privacy and genetic information security",
              "rationale": "Assess concerns and regulatory compliance related to the handling and protection of patient genetic data",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:47:26.063737",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}